Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice
Nanna M, Kolkailah A, Page C, Peterson E, Navar A. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice. JAMA Cardiology 2023, 8: 89-95. PMID: 36322056, PMCID: PMC9631221, DOI: 10.1001/jamacardio.2022.3839.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleGlucagon-Like Peptide 1GlucoseHumansHypoglycemic AgentsPeptidesRetrospective StudiesSodiumSodium-Glucose Transporter 2 InhibitorsConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseUse of SGLT2iPeptide-1 receptor agonistsCotransporter 2 inhibitorsHealth care systemKidney diseaseReceptor agonistCardiovascular diseaseGlucagonlike Peptide-1 Receptor AgonistsStage 5 chronic kidney diseaseEnd-stage kidney diseaseOutpatient health care utilizationDipeptidyl peptidase-4 inhibitorsCare systemQuarter of personsSecondary prevention medicationsGlucose-lowering medicationsRetrospective cohort studyChronic kidney diseasePeptidase-4 inhibitorsElectronic health record dataHealth care utilizationRecent national guidelines